Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Symbio Pharmaceuticals Limited ( (JP:4582) ) just unveiled an update.
SymBio Pharmaceuticals reported first-quarter 2026 consolidated net sales of ¥233 million, down 11.6% year on year, alongside an operating loss of ¥2,341 million and a net loss attributable to owners of the parent of ¥2,401 million. The company’s financial position deteriorated sharply, with total assets falling to ¥2,946 million and shareholders’ equity turning negative, driving the equity ratio to minus 1.7% and underscoring rising financial pressure.
The company maintained a zero-dividend policy for fiscal 2026 and projected full-year net sales of ¥3,891 million, a sharp increase from the prior year, but still expects a substantial full-year net loss of ¥4,331 million. The combination of ongoing losses, negative equity, and reliance on future revenue growth highlights heightened balance-sheet risk and may raise concerns among shareholders and creditors about SymBio’s capital structure and funding needs.
More about Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited is a Japan-based biopharmaceutical company listed on the Tokyo Stock Exchange. The company focuses on developing and commercializing pharmaceutical products, with its revenues currently at a modest scale relative to ongoing research, development, and operating expenses.
Average Trading Volume: 8,661,069
Technical Sentiment Signal: Sell
Current Market Cap: Yen6.98B
For detailed information about 4582 stock, go to TipRanks’ Stock Analysis page.